Category: food and drug administration

1, analysis, analytics, and Cosmetics Act, application, approval, approve, business, Business Analysis, cannabidiol, cannabis, cbd, clinical, clinical trials, compliance, consumer packaged goods, CPG, CSA, dea, derived, deschedule, descheduled, Dravet syndrome, drug, Drug Enforcement Administration, Epidiolex, epilepsy, extraction, FDA, FDCA, Federal, Federal Food, FFDCA, food and drug administration, formulation, government, GW, GW Pharma, hemp, industry, law, legal, legalization, legalize, legislation, Lennox-Gastaut syndrome, license, marijuana, market, medical, medicine, New, patent, pathway, patient, pharma, pharmaceutical, product, Product Development, program, regulation, regulations, regulatory, REMS, safety, schedule, seizures, state, Substances, thc, trial, TSC

How GW Pharma Won CBD

How GW Pharma Won CBD

As of this writing, the United States Food and Drug Administration (FDA) has approved GW Pharma’s CBD drug Epidiolex for treating profound […]

analysis, analytics, business, Business Analysis, cannabidiol, cannabis, cbd, compliance, Congress, congressional, controlled substances act, cultivation, dea, department of justice, derived, DOJ, Drug Enforcement Administration, farm, Farming, FDA, FDCA, Federal, food and drug administration, government, growing, hemp, industry, interim, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, National Institute of Standards and Technology, NIST, plant, plants, political, politics, product, Quality, recreational, reg, regulation, regulations, regulatory, retail, rule, safety, schedule, state, test, Testing, thc, THCA

CBD Industry Caught Between Regulators & Law Enforcement

CBD Industry Caught Between Regulators & Law Enforcement

The consumer-facing CBD industry operates in a regulatory gray zone even as it grows in prominence. Illegal to market as an unapproved […]